MeiraGTx UK II Ltd
10
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
1 terminated/withdrawn out of 10 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
Role: lead
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
Role: lead
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
Role: lead
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Role: lead
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
Role: lead
Natural History Study for Achromatopsia
Role: lead
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Role: lead
Gene Therapy for Achromatopsia (CNGB3)
Role: lead
Gene Therapy for Achromatopsia (CNGA3)
Role: lead
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Role: lead
All 10 trials loaded